New hope for Hard-to-Treat lung cancer: targeted drug combo shows promise
NCT ID NCT07392658
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of the targeted drug amivantamab plus chemotherapy (pemetrexed or gemcitabine) in 33 people with advanced non-small cell lung cancer that has a specific EGFR exon20 insertion mutation. Participants have not had prior treatment and are not healthy enough for standard platinum-based chemotherapy. The study aims to see if the combination shrinks tumors and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- amivantamab (a targeted cancer drug) plus either pemetrexed or gemcitabine (chemotherapy)
- What this could lead to
- If successful, this could offer a new treatment option for people with a specific type of advanced lung cancer who cannot tolerate standard platinum chemotherapy.
- What could go wrong
- This is a small, early-phase trial (33 people) with no control group, so results may not be definitive. Side effects from the drug combination could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
I.F.O. Istituti Fisioterapici Ospitalieri Istituto Nazionale Tumori "Regina Elena", Medical Oncology 2
RECRUITINGRoma, Roma (RM), 00144, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug XTX501 takes aim at Hard-to-Treat cancers
- New drug cocktail targets Hard-to-Treat lung cancer
- Zapping resistant spots: radiation may buy more time for lung cancer patients on targeted drugs
- Gentler chemo combo offers hope for elderly lung cancer patients
- Simple blood test may predict immunotherapy success in lung cancer
- New platform aims to predict lung cancer treatment success